Acquisition of SIMOCTOCOG ALFA 1000 U.I. Powder for Injection FR IV and SIMOCTOCOG ALFA 2000 U.I. Powder for Injection FR IV

This tender involves the acquisition of two specific pharmaceutical products: SIMOCTOCOG ALFA 1000 U.I. Powder for Injection FR IV and SIMOCTOCOG ALFA 2000 U.I. Powder for Injection FR IV. These products are essential for medical treatments and are likely intended for use in healthcare facilities. The tender specifies the need for high-quality pharmaceutical supplies that meet regulatory standards. Interested bidders must demonstrate compliance with relevant health and safety regulations, as well as the ability to deliver these products in a timely manner. The procurement process is expected to follow strict guidelines to ensure transparency and fairness. Bidders should provide detailed information about their manufacturing processes, quality control measures, and previous experience in supplying similar products. The location for delivery and the specific timeline for the procurement process will be outlined in the tender documents. This acquisition is crucial for maintaining adequate medical supplies in healthcare settings, thereby supporting patient care and treatment outcomes.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 627,000.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.